FBR & Co Comments on Alnylam Pharmaceuticals, Inc.’s Q3 2017 Earnings (ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities research analysts at FBR & Co issued their Q3 2017 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Monday. FBR & Co analyst M. Kumar expects that the biopharmaceutical company will post earnings per share of ($1.09) for the quarter. FBR & Co has a “Buy” rating and a $150.00 price objective on the stock.
ALNY has been the subject of a number of other research reports. Ladenburg Thalmann Financial Services set a $90.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, July 17th. BidaskClub raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. JMP Securities upped their target price on shares of Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, September 20th. Piper Jaffray Companies reissued an “overweight” rating and set a $110.00 price target (down previously from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Finally, Chardan Capital reissued a “buy” rating and set a $124.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, September 25th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. Alnylam Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $103.07.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 122.96 on Tuesday. The firm’s 50-day moving average is $110.59 and its 200 day moving average is $83.19. The company’s market cap is $11.28 billion. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $126.16.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The business had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. During the same quarter last year, the business earned ($1.05) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year.
In other news, President Barry E. Greene sold 85,316 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, President Barry E. Greene sold 76,815 shares of the stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the sale, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Tocqueville Asset Management L.P. lifted its position in shares of Alnylam Pharmaceuticals by 25.3% during the third quarter. Tocqueville Asset Management L.P. now owns 20,775 shares of the biopharmaceutical company’s stock worth $2,441,000 after purchasing an additional 4,200 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $349,000. Fayerweather Charles acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $230,000. Aperio Group LLC lifted its position in shares of Alnylam Pharmaceuticals by 5.1% during the third quarter. Aperio Group LLC now owns 16,908 shares of the biopharmaceutical company’s stock worth $1,987,000 after purchasing an additional 823 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in shares of Alnylam Pharmaceuticals by 25.3% during the third quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock worth $92,185,000 after purchasing an additional 158,288 shares in the last quarter. 94.39% of the stock is currently owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.